FI991485A - Ny farmaceutisk komposition - Google Patents

Ny farmaceutisk komposition Download PDF

Info

Publication number
FI991485A
FI991485A FI991485A FI991485A FI991485A FI 991485 A FI991485 A FI 991485A FI 991485 A FI991485 A FI 991485A FI 991485 A FI991485 A FI 991485A FI 991485 A FI991485 A FI 991485A
Authority
FI
Finland
Prior art keywords
pharmaceutical composition
new pharmaceutical
new
composition
pharmaceutical
Prior art date
Application number
FI991485A
Other languages
English (en)
Finnish (fi)
Other versions
FI991485A0 (sv
FI109453B (sv
Inventor
Sari Kallioinen
Lasse Kervinen
Marja Laaksonen
Jarmo Lintulaakso
Mervi Niskanen
Marja Partanen
Marja Ritala
Kari Vahervuo
Matti Virkki
Original Assignee
Orion Yhtymae Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8554988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI991485(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Yhtymae Oyj filed Critical Orion Yhtymae Oyj
Priority to FI991485A priority Critical patent/FI109453B/sv
Publication of FI991485A0 publication Critical patent/FI991485A0/sv
Priority to TW089110218A priority patent/TWI241187B/zh
Priority to PE2000000641A priority patent/PE20010399A1/es
Priority to IT2000MI001450A priority patent/ITMI20001450A1/it
Priority to TR2001/03763T priority patent/TR200103763T2/xx
Priority to YUP-925/01A priority patent/RS50368B/sr
Priority to US09/605,529 priority patent/US6500867B1/en
Priority to PT00944070T priority patent/PT1189608E/pt
Priority to CO00048944A priority patent/CO5180579A1/es
Priority to AT00944070T priority patent/ATE245417T1/de
Priority to ES00944070T priority patent/ES2203495T3/es
Priority to NZ515780A priority patent/NZ515780A/en
Priority to MEP-2008-863A priority patent/ME00520B/me
Priority to AU58306/00A priority patent/AU765932B2/en
Priority to HU0202273A priority patent/HU230395B1/hu
Priority to JP2001507476A priority patent/JP4204783B2/ja
Priority to EP00944070A priority patent/EP1189608B1/en
Priority to KR1020017015737A priority patent/KR100905428B1/ko
Priority to CZ2011-885A priority patent/CZ304416B6/cs
Priority to CZ20014636A priority patent/CZ303010B6/cs
Priority to BRPI0011867A priority patent/BRPI0011867B8/pt
Priority to PL352775A priority patent/PL197818B1/pl
Priority to UA2002010771A priority patent/UA75047C2/uk
Priority to PCT/FI2000/000593 priority patent/WO2001001984A1/en
Priority to SK1923-2001A priority patent/SK286451B6/sk
Priority to ARP000103325A priority patent/AR033796A1/es
Priority to CA002378469A priority patent/CA2378469C/en
Priority to GE4619A priority patent/GEP20043314B/en
Priority to MYPI20002972A priority patent/MY127685A/en
Priority to MXPA01013167A priority patent/MXPA01013167A/es
Priority to DE60004052T priority patent/DE60004052T2/de
Priority to DK00944070T priority patent/DK1189608T3/da
Priority to CNB008095868A priority patent/CN1168440C/zh
Priority to EA200200106A priority patent/EA004503B1/ru
Priority to SI200030190T priority patent/SI1189608T1/xx
Priority to BR0011867-2A priority patent/BR0011867A/pt
Priority to EEP200100716A priority patent/EE05473B1/xx
Priority to FR0008472A priority patent/FR2797587A1/fr
Publication of FI991485A publication Critical patent/FI991485A/sv
Priority to IL146807A priority patent/IL146807A/en
Priority to ZA200109868A priority patent/ZA200109868B/xx
Priority to NO20016203A priority patent/NO330260B1/no
Priority to BG106251A priority patent/BG65364B1/bg
Priority to HR20020088A priority patent/HRP20020088B1/xx
Application granted granted Critical
Publication of FI109453B publication Critical patent/FI109453B/sv
Priority to US10/223,298 priority patent/US6797732B2/en
Priority to HK02108609.4A priority patent/HK1047040B/zh
Priority to JP2008063280A priority patent/JP4885896B2/ja
Priority to NO20110090A priority patent/NO20110090L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
FI991485A 1999-06-30 1999-06-30 Farmaceutisk komposition FI109453B (sv)

Priority Applications (47)

Application Number Priority Date Filing Date Title
FI991485A FI109453B (sv) 1999-06-30 1999-06-30 Farmaceutisk komposition
TW089110218A TWI241187B (en) 1999-06-30 2000-05-26 Levodopa/carbidopa/entacapone pharmaceutical composition
PE2000000641A PE20010399A1 (es) 1999-06-30 2000-06-27 Composicion solida oral que contiene entacapona, levodopa y carbidopa
IT2000MI001450A ITMI20001450A1 (it) 1999-06-30 2000-06-28 Nuova composizione farmaceutica
PCT/FI2000/000593 WO2001001984A1 (en) 1999-06-30 2000-06-29 Levodopa / carbidopa / entacapone pharmaceutical preparation
GE4619A GEP20043314B (en) 1999-06-30 2000-06-29 Pharmaceutical Composition Comprising Entacapone, Levodopa, and Carbidopa
US09/605,529 US6500867B1 (en) 1999-06-30 2000-06-29 Pharmaceutical composition comprising entacapone, levodopa, and carbidopa
PT00944070T PT1189608E (pt) 1999-06-30 2000-06-29 Preparacao farmaceutica de levodopa/carbidopa/entacapona
CO00048944A CO5180579A1 (es) 1999-06-30 2000-06-29 Composicion oral solida que comprende levidopa, carbidopa y entacapone
AT00944070T ATE245417T1 (de) 1999-06-30 2000-06-29 Pharmazeutische zubereitungen auf der basis von levodopa, carbidopa und entacapone
ES00944070T ES2203495T3 (es) 1999-06-30 2000-06-29 Preparado farmaceutico de levodopa/carbidopa/entacapona.
NZ515780A NZ515780A (en) 1999-06-30 2000-06-29 Levodopa / carbidopa / entacapone pharmaceutical preparation
MEP-2008-863A ME00520B (me) 1999-06-30 2000-06-29 Levodop/karbidop/entakapon farmaceutski preparat
AU58306/00A AU765932B2 (en) 1999-06-30 2000-06-29 Levodopa / carbidopa / entacapone pharmaceutical preparation
HU0202273A HU230395B1 (hu) 1999-06-30 2000-06-29 Levodopa /carbidopa/ entacapone tartalmú orálisan adagolható szilárd készítmény, eljárás ennek előállítására és ezt tartalmazó tabletta
JP2001507476A JP4204783B2 (ja) 1999-06-30 2000-06-29 レボドパ／カルビドパ／エンタカポン医薬製剤
EP00944070A EP1189608B1 (en) 1999-06-30 2000-06-29 Levodopa/carbidopa/entacapone pharmaceutical preparation
KR1020017015737A KR100905428B1 (ko) 1999-06-30 2000-06-29 레보도파/카비도파/엔타카폰 약학적 제제
CZ2011-885A CZ304416B6 (cs) 1999-06-30 2000-06-29 Farmaceutická kompozice obsahující entacapon, levodopu a karbidopu a léčivo pro léčení Parkinsonovy choroby
CZ20014636A CZ303010B6 (cs) 1999-06-30 2000-06-29 Perorální pevná kompozice obsahující entacapon, levodopu a karbidopu, zpusoby její prípravy a použití
BRPI0011867A BRPI0011867B8 (pt) 1999-06-30 2000-06-29 preparação farmacêutica de levodopa/carbidopa/entacapona e processo para preparação da mesma
PL352775A PL197818B1 (pl) 1999-06-30 2000-06-29 Stałe doustne kompozycje lewodopa/karbidopa/entakapon, sposób ich wytwarzania oraz ich zastosowanie
UA2002010771A UA75047C2 (en) 1999-06-30 2000-06-29 Fixed dose composition of levodopa, carbidopa and entacapone
TR2001/03763T TR200103763T2 (tr) 1999-06-30 2000-06-29 Levodopa/karbidopa/entakapon farmasötik preparasyonu.
SK1923-2001A SK286451B6 (sk) 1999-06-30 2000-06-29 Perorálna pevná kompozícia obsahujúca entakapon, levodopu a karbidopu a spôsoby jej prípravy a použitie
ARP000103325A AR033796A1 (es) 1999-06-30 2000-06-29 Composicion farmaceutica
CA002378469A CA2378469C (en) 1999-06-30 2000-06-29 An oral solid composition comprising carbidopa, levodopa and entacapone
YUP-925/01A RS50368B (sr) 1999-06-30 2000-06-29 Levodopa/karbidopa/entakapon farmaceutski preparat
MYPI20002972A MY127685A (en) 1999-06-30 2000-06-29 Levodopa/carbidopa/entacapone pharmaceutical preparation
MXPA01013167A MXPA01013167A (es) 1999-06-30 2000-06-29 Preparacion farmaceutica de levodopa / carbidopa / entacapona.
DE60004052T DE60004052T2 (de) 1999-06-30 2000-06-29 Pharmazeutische zubereitungen auf der basis von levodopa, carbidopa und entacapone
DK00944070T DK1189608T3 (da) 1999-06-30 2000-06-29 Farmaceutisk fremstilling på basis af levodopa, carbidopa og entacapon
CNB008095868A CN1168440C (zh) 1999-06-30 2000-06-29 左旋多巴/卡比多巴/恩他卡朋药物制剂
EA200200106A EA004503B1 (ru) 1999-06-30 2000-06-29 Фармацевтическая композиция леводопа/карбидопа/энтакапон
SI200030190T SI1189608T1 (en) 1999-06-30 2000-06-29 Levodopa/carbidopa/entacapone pharmaceutical preparation
BR0011867-2A BR0011867A (pt) 1999-06-30 2000-06-29 Preparação farmacêutica de levodopa/carbidopa/entacapona
EEP200100716A EE05473B1 (et) 1999-06-30 2000-06-29 Levodopa/karbidopa/entakapooni farmatseutiline preparaat, selle valmistamise meetod ja kasutamine
FR0008472A FR2797587A1 (fr) 1999-06-30 2000-06-30 Nouvelle composition pharmaceutique
IL146807A IL146807A (en) 1999-06-30 2001-11-29 Preparation of pharmaceutical preparations of Lavadopa / Carbidopa / Antacapone
ZA200109868A ZA200109868B (en) 1999-06-30 2001-11-29 Levodopa/carbidopa/entacapone pharmaceutical preparation.
NO20016203A NO330260B1 (no) 1999-06-30 2001-12-18 Oral, fast sammensetning omfattende levodopa/carbidopa/entacapon, fremgangsmate for fremstilling derav, samt anvendelse av en sammensetning omfattende levodopa/carbidopa/entacapon for fremstilling av et medikament til behandling av Parkinsons sykdom.
BG106251A BG65364B1 (bg) 1999-06-30 2001-12-20 Фармацевтичен препарат леводопа/карбидопа/ентакапон
HR20020088A HRP20020088B1 (en) 1999-06-30 2002-01-29 Levodopa/carbidopa/entacapone pharmaceutical preparation
US10/223,298 US6797732B2 (en) 1999-06-30 2002-08-20 Pharmaceutical composition comprising entracapone, levodopa, and carbidopa
HK02108609.4A HK1047040B (zh) 1999-06-30 2002-11-29 左旋多巴/卡比多巴/恩他卡朋藥物製劑
JP2008063280A JP4885896B2 (ja) 1999-06-30 2008-03-12 レボドパ／カルビドパ／エンタカポン医薬製剤
NO20110090A NO20110090L (no) 1999-06-30 2011-01-19 Stabil fast oral sammensetning omfattende levodopa, carbidopa, og entacapon

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI991485A FI109453B (sv) 1999-06-30 1999-06-30 Farmaceutisk komposition
FI991485 1999-06-30

Publications (3)

Publication Number Publication Date
FI991485A0 FI991485A0 (sv) 1999-06-30
FI991485A true FI991485A (sv) 2000-12-31
FI109453B FI109453B (sv) 2002-08-15

Family

ID=8554988

Family Applications (1)

Application Number Title Priority Date Filing Date
FI991485A FI109453B (sv) 1999-06-30 1999-06-30 Farmaceutisk komposition

Country Status (42)

Country Link
US (2) US6500867B1 (sv)
EP (1) EP1189608B1 (sv)
JP (2) JP4204783B2 (sv)
KR (1) KR100905428B1 (sv)
CN (1) CN1168440C (sv)
AR (1) AR033796A1 (sv)
AT (1) ATE245417T1 (sv)
AU (1) AU765932B2 (sv)
BG (1) BG65364B1 (sv)
BR (2) BR0011867A (sv)
CA (1) CA2378469C (sv)
CO (1) CO5180579A1 (sv)
CZ (2) CZ304416B6 (sv)
DE (1) DE60004052T2 (sv)
DK (1) DK1189608T3 (sv)
EA (1) EA004503B1 (sv)
EE (1) EE05473B1 (sv)
ES (1) ES2203495T3 (sv)
FI (1) FI109453B (sv)
FR (1) FR2797587A1 (sv)
GE (1) GEP20043314B (sv)
HK (1) HK1047040B (sv)
HR (1) HRP20020088B1 (sv)
HU (1) HU230395B1 (sv)
IL (1) IL146807A (sv)
IT (1) ITMI20001450A1 (sv)
ME (1) ME00520B (sv)
MX (1) MXPA01013167A (sv)
MY (1) MY127685A (sv)
NO (2) NO330260B1 (sv)
NZ (1) NZ515780A (sv)
PE (1) PE20010399A1 (sv)
PL (1) PL197818B1 (sv)
PT (1) PT1189608E (sv)
RS (1) RS50368B (sv)
SI (1) SI1189608T1 (sv)
SK (1) SK286451B6 (sv)
TR (1) TR200103763T2 (sv)
TW (1) TWI241187B (sv)
UA (1) UA75047C2 (sv)
WO (1) WO2001001984A1 (sv)
ZA (1) ZA200109868B (sv)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (sv) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaceutisk komposition
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
US20040180086A1 (en) * 2002-10-11 2004-09-16 Zebunnissa Ramtoola Gastro-retentive levodopa delivery form
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2006037061A2 (en) * 2004-09-28 2006-04-06 Farouk Karoum Compositions and methods of using d-dopa to treat parkinson's disease
EP1812070B1 (en) 2004-11-10 2013-10-02 Orion Corporation Treatment of restless legs syndrome
EA013161B1 (ru) * 2005-06-08 2010-02-26 Орион Корпорейшн Дозированная форма для перорального применения
AU2012216377C1 (en) * 2005-06-08 2013-10-10 Orion Corporation Oral dosage form
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
SI1907382T1 (sl) 2005-07-26 2015-10-30 Bial-Portela & Ca S.A., Nitrokateholni derivati kot inhibitorji COMT
WO2007016190A2 (en) * 2005-07-28 2007-02-08 Duke University Antiparkinsonian action of phenylisopropylamines
US20090012170A1 (en) * 2005-09-21 2009-01-08 Helena Nissinen Treatment of symptoms of motor dysfunction
EP1945188A2 (en) * 2005-11-07 2008-07-23 Teva Pharmaceutical Industries Ltd. Levodopa compositions
EP1954256A2 (en) * 2005-11-09 2008-08-13 Torrent Pharmaceuticals Ltd Pharmaceutical composition comprising a compound having a catechol moiety and an alkalising agent
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
CN100384411C (zh) * 2006-03-17 2008-04-30 北京科信必成医药科技发展有限公司 卡左双多巴口腔崩解片
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
EP2104424A4 (en) 2006-10-30 2011-06-15 Wockhardt Research Center PHARMACEUTICAL COMPOSITIONS COMPRISING ENTACAPONE, LEVODOPA, AND CARBIDOPA
EP2063867A2 (en) * 2006-12-22 2009-06-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008081268A2 (en) * 2006-12-27 2008-07-10 Wockhardt Research Centre Pharmaceutical compositions of entacapone
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
LT2481410T (lt) 2007-01-31 2016-11-10 Bial - Portela & Ca., S.A. Nitrokatecholio dariniai kaip komt inhibitoriai vartojami konkrečiu dozavimo režimu
US20110171275A1 (en) * 2007-08-20 2011-07-14 Team Academy Of Pharmaceutical Science Gastroretentive drug delivery system, preparation method and use thereof
AU2009211030B2 (en) * 2008-02-06 2013-12-05 Wockhardt Research Centre Pharmaceutical compositions of entacapone co-micronized with sugar alcohols
EP2252284B1 (en) * 2008-02-06 2011-05-25 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
JP2011514380A (ja) 2008-03-17 2011-05-06 バイアル−ポルテラ アンド シーエー，エス．エー． ５−［３−（２，５−ジクロロ−４，６−ジメチル−１−オキシ−ピリジン−３−イル）［１，２，４］オキサジアゾール−５−イル］−３−ニトロベンゼン−１，２−ジオールの結晶形
US20110229566A1 (en) * 2008-08-22 2011-09-22 Yatendra Kumar Gupta Single Unit Oral Dose Pharmaceutical Composition Comprising Levodopa, Carbidopa And Entacapone Or Salts Thereof
KR101667762B1 (ko) * 2008-08-22 2016-10-20 욱크하르트 리미티드 엔타카폰 또는 이의 염의 서방형 약학 조성물
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
AU2010231961B2 (en) 2009-04-01 2015-05-21 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
PT3192500T (pt) * 2009-05-19 2021-01-05 Neuroderm Ltd Composições para a administração contínua de inibidores da dopa decarboxilase
US9750702B2 (en) 2009-12-25 2017-09-05 Innopharmax, Inc. Pharmaceutical composition for treating parkinson's disease and preparation method thereof
EA026419B1 (ru) * 2010-03-04 2017-04-28 Орион Корпорейшн Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
DE102010023828A1 (de) 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
SG10201509316SA (en) * 2010-11-15 2015-12-30 Neuroderm Ltd Continuous Administration Of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors And Compositions For Same
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012147099A1 (en) 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
BR112013027219A2 (pt) * 2011-04-26 2016-12-27 Innopharmax Inc composição de entacapone, processo para preparar a composição de entacapone, composição farmacêutica, e, uso da composição de entacapone
JP6456143B2 (ja) 2011-12-13 2019-01-23 ノヴィファーマ，エス．アー． カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
DK2854764T3 (en) 2012-06-05 2019-04-08 Neuroderm Ltd COMPOSITIONS CONTAINING APOMORPHINE AND ORGANIC ACIDS, AND APPLICATIONS THEREOF
BR112015022390A8 (pt) * 2013-03-13 2019-11-26 Neuroderm Ltd uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
CA2926082C (en) 2013-10-07 2022-06-14 Impax Laboratories, Inc. Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
ES2967693T3 (es) 2014-03-13 2024-05-03 Neuroderm Ltd Composiciones del inhibidor de la dopa descarboxilasa
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP4356907A1 (en) * 2014-09-04 2024-04-24 LobSor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comtinhibitor and method of administration thereof
RU2017120184A (ru) 2014-11-28 2018-12-28 БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. Лекарства для замедления течения болезни паркинсона
EP3236957A1 (en) 2014-12-23 2017-11-01 Pharmathen S.A. Levodopa/carbidopa/entacapone pharmaceutical preparation and method for preparing the same
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
WO2018011181A1 (en) * 2016-07-11 2018-01-18 Contera Pharma Aps Pulsatile drug delivery system for treating morning akinesia
EP3500246B1 (en) 2016-08-18 2021-08-04 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi Antiparkinson tablet formulation with improved dissolution profile
WO2019145773A1 (en) 2017-12-15 2019-08-01 Nos Life Sciences Corporation Liposomal-encapsulated formulations
AU2019237857A1 (en) 2018-03-23 2020-10-08 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE4101873C2 (de) 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB2321190B (en) 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
US6599530B2 (en) 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (sv) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaceutisk komposition

Also Published As

Publication number Publication date
ZA200109868B (en) 2003-05-28
DK1189608T3 (da) 2003-11-10
MXPA01013167A (es) 2002-07-02
HRP20020088B1 (en) 2007-05-31
CZ304416B6 (cs) 2014-04-23
IL146807A (en) 2006-10-05
BR0011867A (pt) 2002-03-05
DE60004052T2 (de) 2004-04-15
ITMI20001450A0 (it) 2000-06-28
YU92501A (sh) 2004-09-03
AR033796A1 (es) 2004-01-07
EE05473B1 (et) 2011-10-17
JP2008156373A (ja) 2008-07-10
NO330260B1 (no) 2011-03-14
CA2378469C (en) 2009-10-06
AU765932B2 (en) 2003-10-02
HK1047040A1 (en) 2003-02-07
PE20010399A1 (es) 2001-04-10
WO2001001984A1 (en) 2001-01-11
GEP20043314B (en) 2004-02-10
SI1189608T1 (en) 2004-04-30
JP4204783B2 (ja) 2009-01-07
SK286451B6 (sk) 2008-10-07
PL352775A1 (en) 2003-09-08
US6797732B2 (en) 2004-09-28
DE60004052D1 (de) 2003-08-28
EP1189608A1 (en) 2002-03-27
CN1168440C (zh) 2004-09-29
HUP0202273A3 (en) 2002-11-28
CA2378469A1 (en) 2001-01-11
CO5180579A1 (es) 2002-07-30
HK1047040B (zh) 2005-04-29
PT1189608E (pt) 2003-12-31
BG65364B1 (bg) 2008-04-30
NZ515780A (en) 2004-06-25
RS50368B (sr) 2009-11-10
EP1189608B1 (en) 2003-07-23
ITMI20001450A1 (it) 2001-12-28
US6500867B1 (en) 2002-12-31
EA200200106A1 (ru) 2002-06-27
NO20016203L (no) 2002-02-25
SK19232001A3 (sk) 2002-06-04
NO20110090L (no) 2002-02-25
ME00520B (me) 2011-10-10
EE200100716A (et) 2003-02-17
KR100905428B1 (ko) 2009-06-30
MY127685A (en) 2006-12-29
HRP20020088A2 (en) 2005-10-31
BRPI0011867B8 (pt) 2021-05-25
TR200103763T2 (tr) 2002-04-22
ES2203495T3 (es) 2004-04-16
ATE245417T1 (de) 2003-08-15
CN1358090A (zh) 2002-07-10
BRPI0011867B1 (pt) 2019-01-08
FR2797587A1 (fr) 2001-02-23
BG106251A (en) 2002-08-30
KR20020010155A (ko) 2002-02-02
TWI241187B (en) 2005-10-11
JP2003503454A (ja) 2003-01-28
EA004503B1 (ru) 2004-04-29
NO20016203D0 (no) 2001-12-18
HUP0202273A2 (en) 2002-10-28
CZ303010B6 (cs) 2012-02-29
UA75047C2 (en) 2006-03-15
PL197818B1 (pl) 2008-04-30
AU5830600A (en) 2001-01-22
FI991485A0 (sv) 1999-06-30
HU230395B1 (hu) 2016-04-28
CZ20014636A3 (cs) 2002-05-15
JP4885896B2 (ja) 2012-02-29
US20030017201A1 (en) 2003-01-23
FI109453B (sv) 2002-08-15

Similar Documents

Publication Publication Date Title
FI991485A0 (sv) Ny farmaceutisk komposition
NO20015175D0 (no) Farmasöytisk sammensetning
NO20025450L (no) Ny farmasöytisk sammensetning
NO20021116D0 (no) Ny sammensetning
ID27415A (id) Komposisi farmaseutik
PT1242087E (pt) Composicoes farmaceuticas
NO20012915D0 (no) Ny farmasöytisk formulering
IS5046A (is) Lyfjasamsetningar
DK1524266T3 (da) Farmaceutisk sammensætning
NO20005913L (no) Legemiddelsammensetning
FR2775596B1 (fr) Nouvelles compositions pharmaceutiques
NO20021115D0 (no) Ny sammensetning
ID29262A (id) Komposisi farmasi
ID27201A (id) Komposisi farmasi
NO20022606L (no) Farmasöytiske kombinasjoner
DE69943245D1 (de) Gaserzeugende zusammensetzung
PT1239832E (pt) Composicoes farmaceuticas
FI4488U1 (sv) Farmaceutisk komposition
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida
DE60020682D1 (de) Resorcinenthaltende zusammensetzung
FR2779145B1 (fr) Nouvelles compositions pharmaceutiques
ID26215A (id) Komposisi farmasi
NO20004816D0 (no) Ny farmasøytisk formulering
ID27329A (id) Komposisi penghambat
NO20022845D0 (no) Limsammensetning

Legal Events

Date Code Title Description
PC Transfer of assignment of patent

Owner name: ORION CORPORATION

Free format text: ORION CORPORATION

MA Patent expired